Stop Compromising on Speed or Accuracy in Antibody Discovery
The article outlines how antibody discovery teams can simultaneously improve speed and accuracy by adopting a collaborative workflow involving three key steps—target identification using a query tool for antibody searches, target screening with customizable parameters and integrated data management, and candidate selection through bioassay data association and sequence alignment—highlighting Dotmatics Biology Solution for Antibody Discovery as a tool to streamline these processes.
The choice between speed and accuracy is one that many antibody discovery teams have been forced to make as the complexity of their workflows grows beyond the capabilities of their disconnected research tools.
Instead of compromising on one and focusing on the force that is deemed more important, a trio of experts show how to enhance both speed and accuracy for antibody discovery research with a collaborative antibody selection workflow.
Three Key Steps in an Antibody Discovery Workflow
The experts discuss three critical steps for achieving a collaborative approach:
-
Step 1 - Target Identification:
- Use a forms-based query tool to search registered antibodies for targets of interest. Search criteria may be broad-ranging, such as all antibodies in an overarching project, or more granular, such as antibodies that had titer results in a specific range.
- Users can easily request additional analyses from their screening group.
-
Step 2 - Target Screening:
- Customize screening parameters
- Manage plate setup
- Define controls
- Perform analyses (such as IC50)
- Knock out wells
- Visualize results in different ways (plates, samples, layers, overlays, etc.)
- Upload associated files
- Set-up countersigning requirements
The presenters demonstrate efficiency gains when screening teams work within the same system as project scientists. They show how to quickly download requested batches, add them to a new experiment, and automatically tie results back to samples.
-
Step 3 - Candidate Selection:
- Narrow down candidates by associating bioassay data (e.g., IC50 values) with annotated sequence data
- Filter sequences based on assay data
- Align whole sequences, or regions of interest, to better understand how they relate to each other
Enhance Both the Speed and Accuracy of Your Research
To help teams overcome the speed and accuracy conundrum, Dotmatics launched the Dotmatics Biology Solution for Antibody Discovery—the market’s first true end-to-end antibody workflow solution. Delivered on Dotmatics’ data platform, the solution unites time-tested antibody discovery tools, including Geneious Biologics, Geneious Prime, SnapGene, and GraphPad Prism, to let researchers achieve both speed and accuracy as they make, test, and select therapeutic antibody candidates.
How does it do this? Here are a few of the ways:
-
Efficient data handling:
- Data are easily collected, standardized, and progressed throughout the discovery workflow, without time-consuming or error-prone data wrangling. Hours of preparing, mapping, and moving data are now replaced with just a few button clicks.
-
Streamlined workflows:
- Researchers can create cross-team workflows that leverage trusted tools for antibody sequencing, bioinformatics, assay screening, experiment planning, and more. Customizable, pre-built templates help teams hit the ground running.
-
Better collaboration:
- Teams can securely make requests, manage workload, and share insights to drive better decisions and keep projects moving.
Researchers are encouraged to get a demonstration of the Antibody Discovery workflow to see how they can leverage a solution that accelerates antibody research while also improving the accuracy of data and findings.
Related
Biologics Drug Discovery
The Dotmatics Biology Solution offers comprehensive end-to-end data management and analysis tools tailored for biologics drug discovery—including antibodies, CAR-T cells, and RNA therapeutics—facilitating collaborative workflows in molecular cloning, protein production, biologics registration, and assay data analysis to accelerate innovation and streamline complex research processes.
The Antibody Engineering & Therapeutics Conference
Dotmatics is sponsoring the Antibody Engineering & Therapeutics US 2022 conference on December 5 at Marriott Marquis San Diego, featuring innovations in antibody discovery and related fields, with a highlighted talk by Senior Solutions Architect Melanie Nelson on streamlining antibody discovery using Dotmatics Biology Solution from 1:15pm to 1:45pm PST at Booth 509.
Four Moves Biotechs Can Make to Stay Competitive as Investor Confidence Shifts
As investor confidence in biotech has shifted from rapid, high-risk funding to more cautious, data-driven investment with longer timelines and stricter demands, biotechs must adapt by embracing innovative R&D platforms, demonstrating clear value through validated data and milestones, exploring flexible partnership models like co-development and joint ventures, and strategically managing growth to remain competitive in a market with tighter capital and evolving investor expectations.
Dotmatics Streamlines Workflow for Antibody Research
Dotmatics has launched its Biology Solution for Antibody Discovery, a cloud-based, end-to-end software platform that integrates with popular scientific tools like Geneious, SnapGene, and GraphPad Prism to centralize data management, automate workflows, reduce errors, and accelerate antibody research amid a rapidly growing antibody therapy market projected to reach up to $700 billion by 2032.
Dotmatics at Antibody Engineering & Therapeutics 2024
Dotmatics will exhibit at the Antibody Engineering & Therapeutics Conference from December 15-18, 2024, at the Marriott Marquis San Diego Marina (booth 313), featuring a presentation by Christian Olsen on December 16 about how Geneious Luma enhances therapeutic antibody engineering through adaptive workflows and data aggregation.
Our 11 Most-Read Blogs of 2023: AI, Biologics, ELNs, and More
Dotmatics' top blogs of 2023 highlight key scientific advancements including the convergence of small molecule and biologic drug development, the integration and comparison of LIMS and ELN systems for enhanced lab data management, and strategies to minimize human errors in biologics research through automation and calibration.